ZHEJIANG WECOME PHARMACEUTICAL COMPANY LIMITED

Zhejiang Wecome Pharmaceutical Company Limited

300878

CNE1000047P9

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 03:30:00 26/06/2024 am IST			5-day change	1st Jan Change
14.85 ^CNY	+3.41%		-0.20%	-41.47%

22/05	Zhejiang Wecome Pharmaceutical Company Limited Announces Final Cash Dividend on A Shares for the Year 2023, Payable on 29 May 2024	CI
28/04	Zhejiang Wecome Pharmaceutical Company Limited Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Tranche Update on Zhejiang Wecome Pharmaceutical Company Limited's Equity Buyback Plan announced on February 7, 2024.

February 27, 2024 at 01:59 pm IST

From February 7, 2024 to February 27, 2024, the company has repurchased 2,739,026 shares, representing 1.89% for CNY 50 million. With this, the company has completed the repurchase of 2,739,026 shares, representing 1.89% for CNY 50 million under the buyback announced on February 7, 2024.

Latest news about Zhejiang Wecome Pharmaceutical Company Limited

Zhejiang Wecome Pharmaceutical Company Limited Announces Final Cash Dividend on A Shares for the Year 2023, Payable on 29 May 2024	22/05	CI
Zhejiang Wecome Pharmaceutical Company Limited Reports Earnings Results for the First Quarter Ended March 31, 2024	28/04	CI
Zhejiang Wecome Pharmaceutical Company Limited Reports Earnings Results for the Full Year Ended December 31, 2023	19/04	CI
Tranche Update on Zhejiang Wecome Pharmaceutical Company Limited's Equity Buyback Plan announced on February 7, 2024.	27/02	CI
Zhejiang Wecome Pharmaceutical Company Limited's Equity Buyback announced on February 7, 2024, has closed with 2,739,026 shares, representing 1.89% for CNY 50 million.	27/02	CI
Zhejiang Wecome Pharmaceutical Company Limited announces an Equity Buyback for CNY 50 million worth of its shares.	07/02	CI
Zhejiang Wecome Pharmaceutical Company Limited authorizes a Buyback Plan.	07/02	CI
Zhejiang Wecome Pharmaceutical Company Limited Reports Earnings Results for the Nine Months Ended September 30, 2023	29/23/29	CI
Zhejiang Wecome Pharmaceutical Company Limited Reports Earnings Results for the Half Year Ended June 30, 2023	28/23/28	CI
Certain A Shares of Zhejiang Wecome Pharmaceutical Company Limited are subject to a Lock-Up Agreement Ending on 24-AUG-2023.	24/23/24	CI
Zhejiang Wecome Pharmaceutical Company Limited Reports Earnings Results for the First Quarter Ended March 31, 2023	27/23/27	CI
Zhejiang Wecome Pharmaceutical Company Limited Reports Earnings Results for the Full Year Ended December 31, 2022	27/23/27	CI
Zhejiang Wecome Pharmaceutical Company Limited Reports Earnings Results for the Nine Months Ended September 30, 2022	27/22/27	CI
Zhejiang Wecome Pharma to Issue $95 Million Convertible Bonds	12/22/12	MT
Zhejiang Wecome Pharmaceutical Company Limited Reports Earnings Results for the Half Year Ended June 30, 2022	29/22/29	CI
Hangzhou Haishan Pharmaceutical Equipment Co., Ltd. announced that it expects to receive CNY 20 million in funding from Zhejiang Wecome Pharmaceutical Company Limited	18/22/18	CI
Zhejiang Wecome Pharmaceutical Company Limited Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2021, Payable on 17 June 2022	14/22/14	CI
Zhejiang Wecome Pharmaceutical Company Limited Approved Cash Dividend for the Year 2021	08/22/08	CI
Zhejiang Wecome Pharmaceutical Company Limited Proposes Final Cash Dividend for the Year 2021	30/22/30	CI
Zhejiang Wecome Pharmaceutical Company Limited Reports Earnings Results for the Full Year Ended December 31, 2021	28/22/28	CI
Zhejiang Wecome Pharmaceutical Company Limited Reports Earnings Results for the First Quarter Ended March 31, 2022	28/22/28	CI
LBX Pharmacy Chain Joint Stock Company singed an Asset Purchase Agreement to acquire a 71.9% stake in Hunan Huairen Great Health Industry Development Co., Ltd. from group of sellers for CNY 1.6 billion.	07/22/07	CI
Zhejiang Wecome Pharmaceutical Company Limited Reports Earnings Results for the Nine Months Ended September 30, 2021	27/21/27	CI
Zhejiang Jingning Oujiang Capsule Co., Ltd. announced that it expects to receive CNY 8.92 million in funding from Zhejiang Wecome Pharmaceutical Company Limited and other investors	27/21/27	CI
Zhejiang Wecome Pharmaceutical Company Limited completed the acquisition of 70% of stake in Zhejiang Jingning Oujiang Capsule Co., Ltd. from Wang Shiguo and Wang Linsu.	15/21/15	CI

Chart Zhejiang Wecome Pharmaceutical Company Limited

Duration

Period

Chart Zhejiang Wecome Pharmaceutical Company Limited

More charts

Company Profile

Zhejiang Wecome Pharmaceutical Co Ltd is a China-based company mainly engaged in the research, development, production and sales of modern Chinese medicine and western medicine. The Company's main products include Yinhuang dripping pills, motherwort soft capsules, motherwort dispersible tablets, Guci capsules, Fengliao Changweikang dispersible tablets, ginseng Jianpi tablets and other Chinese patent medicines, as well as western medicines such as roxithromycin soft capsules. Its production dosage forms cover hard capsules, tablets, granules, soft capsules, and pills. The Company mainly conducts its businesses in the China market.

Sector

Pharmaceuticals

Calendar

27/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ZHEJIANG WECOME PHARMACEUTICAL COMPANY LIMITED	-41.47%	281M
ELI LILLY AND COMPANY	+55.28%	815B
NOVO NORDISK A/S	+44.25%	654B
JOHNSON & JOHNSON	-6.39%	354B
MERCK & CO., INC.	+22.20%	337B
ABBVIE INC.	+10.76%	302B
ASTRAZENECA PLC	+18.45%	247B
ROCHE HOLDING AG	+2.09%	229B
NOVARTIS AG	+13.03%	219B
AMGEN INC.	+9.58%	171B